Among patients with advanced gastric and GEJ cancer, or esophageal adenocarcinoma, treatment with first-line Opdivo and chemo demonstrated deep responses.

CheckMate 649 trial showed sustained efficacy with frontline nivolumab plus chemotherapy vs chemotherapy alone in patients with gastric cancers.

The FDA has accepted a BLA for treatment with RP1 in combination with Opdivo for patients with advanced melanoma who have progressed on prior therapy.

Replimune Group, Inc. REPL announced that the FDA has accepted the biologics license application (BLA) for its lead pipeline ...

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Replimune Group (REPL – Research Report), with a price ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

Jan. 15, 2025 — Scientists have come up with a drug that is a potential candidate for tackling memory deficits in the early stages of the disease in rodents. ... New Innovative Local Treatment ...

The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

An FDA committee’s September 2024 vote to limit the use of Merck’s Keytruda and BMS’ Opdivo in stomach and esophageal cancers ...

Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you. Daily news – Get the most important news from ...

(This Dec. 27 story has been corrected to say Opdivo Qvantig has been approved to treat most previously approved tumor indications, not all previously approved tumor indications, in paragraph 5) By ...